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Abstract: Adalimumab is a fully human IgG1 monoclonal antibody that speciﬁ  cally binds to 
tumor necrosis factor (TNF)-alpha, and is administered by subcutaneous injection. The mecha-
nism of action is based on both the neutralization of TNF-alpha bioactivity and the induction 
of apoptosis of TNF-expressing mononuclear cells. The drug is approved for the treatment of 
rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis (PsA), and recently also for 
the treatment of Crohn’s disease. The effectiveness of adalimumab in psoriasis was previously 
suggested by the subset analysis of patients enrolled in PsA trials who were affected by con-
comitant psoriasis, and recently conﬁ  rmed by a phase II trial and the preliminary results from 
phase III trials in moderate to severe psoriasis. These results demonstrate that adalimumab is 
effective in improving psoriasis and quality of life, with sustained effects over  1-year treat-
ment period. The safety data from psoriasis studies were similar to those of previous studies in 
other diseases. The risk of adverse events did not appear to increase with continuous long-term 
exposure to adalimumab.
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General aspects of psoriasis
Psoriasis is a chronic inﬂ  ammatory immune-mediated skin disease that affects 
1%–3% of general population. The disease is characterized by hyperproliferation and 
abnormal differentiation of keratinocytes, vascular changes in the papillary dermis, 
intraepidermal accumulation of neutrophils and dermal inﬂ  ammation with prominent 
lymphocytic inﬁ  ltrate. The development of psoriasis has a multifactorial nature result-
ing from the interaction between genetic predisposition and environmental factors. 
Pathogenic mechanisms are considered to be secondary to an abnormal immune 
response, with an aberrant regulation of both the adaptative (CD4+ Th1 lymphocytes 
and CD8+ type-1 T-cells) and the innate immunity (dendritic cells, macrophages, 
keratinocytes) resulting in a complex network of cytokines, chemokines and growth 
factors (Gaspari 2006).
Among the different clinical variants, plaque psoriasis is the most frequent, 
accounting for more than 80% of cases. Psoriatic plaques are papulo-squamous lesions 
with variable dimensions and degree of erythema, scaling and inﬁ  ltration. They can 
be localized or diffuse and are often itchy. Nail involvement is common, especially 
in patients with concomitant psoriatic arthritis (PsA). PsA is now considered more 
aggressive than previously thought and has been reported to occur in 6% up to 42% of 
psoriatic patients, usually after the appearance of skin lesions (Gladman et al 2005). 
Psoriasis has a relevant inﬂ  uence on quality of life, causing social and physical dis-
ability, employment problems, productivity loss, feeling of stigmatization, depres-
sion, and other psychological problems. The psychosocial and economic burdens 
of psoriasis are signiﬁ  cant (Kimball et al 2005; Hazard et al 2006; Sohn et al 2006). 
Overall direct and indirect costs of treating psoriasis are high, especially for patients Biologics: Targets & Therapy 2007:1(2) 94
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with recalcitrant disease, and are likely to be underestimated. 
Therapeutic management of psoriasis is complex and 
requires an individualized approach. The choice of treatment 
is usually inﬂ  uenced by disease severity, location of lesions, 
impairment of quality of life, response to previous treatments, 
presence of concomitant PsA or other comorbidities. Severity 
of psoriasis can be deﬁ  ned by the Psoriasis Area and Severity 
Index (PASI) (Fredriksen and Petterson 1978) and the body 
Surface Area (BSA) affected, which are objective measures 
used by regulatory agencies and in research setting. Tradi-
tional approaches to moderate to severe disease (with PASI at 
least of 10 and BSA involvement 10%) include ultraviolet 
light therapy with UVB or with psoralens and UVA (PUVA), 
and systemic agents, such as cyclosporine, methotrexate 
(MTX), and acitretin. The use of these approaches can be 
limited by conditions which contraindicate their use, lack 
of efﬁ  cacy, dose-dependent and time-dependent toxicity, or 
inconvenience. Common problems encountered in clinical 
practice with the use of traditional therapies are patient’s 
dissatisfaction and non-adherence to the treatment regimen 
prescribed (Nijsten et al 2005; Christophers et al 2006; 
Richards et al 2006). Moreover, treatment success does not 
necessarily correspond to complete clearance and may have 
no impact on psychological distress (Fortune et al 2004; 
Feldman et al 2005).
The recent introduction of biologic agents (mono-
clonal antibodies or fusion proteins) interfering with 
specific pathogenic targets has widened the possibilities 
of treating adult patients with chronic moderate to se-
vere disease who are candidates for systemic therapy or 
phototherapy. Biologic agents currently available for the 
treatment of psoriasis include drugs which act by binding 
to T-lymphocyte antigens, eg, alefacept (which is not 
yet approved by EMEA) and efalizumab, or by targeting 
tumor necrosis factor (TNF), eg, the fusion protein etan-
ercept and the chimeric monoclonal antibody infliximab. 
In European countries, biologic agents are approved for 
the treatment of adults with moderate to severe plaque 
psoriasis who failed to respond to, or have a contrain-
dication to, or are intolerant to other systemic therapies 
including cyclosporin, MTX or PUVA. TNF-blockers are 
also indicated for the treatment of PsA.
The serendipitous discovery of the effectiveness of anti-
TNF biologics in psoriasis has suggested the crucial role of 
this cytokine, which can be implicated in multiple events of 
psoriasis-related inﬂ  ammation: attraction of leucocytes into 
the skin, activation of dendritic cells and T lymphocytes, 
release of epithelial and vascular growth factors, synthesis of 
cytokines, chemokines and other proinﬂ  ammatory mediators 
via activation of NF-kappaB (Victor et al 2003).
Adalimumab: pharmacological 
proﬁ  le
Indications, dosage and administration
Adalimumab (Humira®, D2E7, Abbott Laboratories, Abbott 
Park, IL, USA) is a fully human IgG1 monoclonal antibody 
that speciﬁ  cally binds to TNF-alpha. The drug is produced 
by recombinant DNA technology in a mammalian cell 
expression system and is puriﬁ  ed by a process that includes 
speciﬁ  c viral inactivation and removal steps. It consists of 
1330 amino acids and has a molecular weight of approxi-
mately 148 kDa.
In most countries, including the U.S. and Europe, adali-
mumab is approved for treatment of adults with rheumatoid 
arthritis (RA), PsA and ankylosing spondylitis. The ﬁ  rst 
indication was treatment of RA, for which adalimumab 
received the approval by the FDA in December 2002. The 
recommended dosage of adalimumab is 40 mg administered 
every other week (EOW) as a subcutaneous (s.c.) injection. 
The use of MTX in PsA is facultative, and, in RA patients 
not taking concomitant MTX, the dosing frequency can be 
increased to 40 mg every week to obtain additional beneﬁ  t. 
In February 2007, the FDA approved adalimumab to treat 
adult patients with moderately to severely active Crohn’s 
disease (at the dosage of 160 mg at week 0, 80 mg at week 
2, followed by a maintenance dose of 40 mg EOW starting 
at week 4). On the 2nd of July 2007, adalimumab received 
the approval for treatment of severe active Crohn’s disease 
also by the EMEA, which recommends the combination 
with corticosteroids during the induction phase, except for 
patients who are intolerant to steroids or in whom continued 
treatment with corticosteroids is inappropriate. At the time of 
writing this review, adalimumab is in phase III clinical trials 
for psoriasis and is expected to be approved for the treatment 
of this disease within the end of 2007.
The drug product is supplied as either a single-use, 1 
mL preﬁ  lled glass syringe or a single-use, preﬁ  lled 1 mL 
autoinjector (the pen), both providing 40 mg of adalimumab. 
The two delivery systems are FDA- and EMEA-approved. The 
pen was developed to facilitate self-injection by patients with 
physically limiting diseases. Systemic exposure and safety 
proﬁ  les of adalimumab were comparable between the two de-
vices (Paulson et al 2007). A phase II, open-label, single-arm 
study assessed patient preference of the pen versus the syringe 
in 52 patients with active RA who had been self-administering Biologics: Targets & Therapy 2007:1(2) 95
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adalimumab 40 mg EOW via a syringe for at least 3 months 
(Kivitz et al 2006). Overall, 76.9% of patients reported that 
the pen was less painful than the syringe and 88.5% preferred 
the pen. The majority of patients considered the pen easier to 
use (94.2%), more convenient (92.3%), requiring less time to 
inject (82.7%), and safer (88.5%).
Pharmacokinetics and immunogenicity
Pharmacokinetic studies showed that, after a single 40 mg 
dose, absorption and distribution of adalimumab appeared 
to be slow, with an average absolute bioavailability of 64%. 
The serum adalimumab trough levels at steady state increased 
approximately proportionally with dose following 20, 40 
and 80 mg EOW and every week s.c. dosing, and increased 
also with concomitant MTX. As compared to RA patients, 
treatment with 40 mg EOW in PsA patients resulted in a 
slight increase of mean steady-state trough concentrations. 
MTX was found to reduce the apparent clearance of adali-
mumab after single and multiple dosing by 29% and 44% 
respectively. In long-term studies over two years, there was 
no evidence of changes in clearance over time. Population 
pharmacokinetic analyses revealed a trend toward lower 
apparent clearance with increasing age and toward higher 
clearance with increasing body weight and in the presence of 
anti-adalimumab antibodies (AAA). In fact, the serum levels 
of free adalimumab (not bound to AAA) were observed to be 
lower in patients with detectable AAA. Minor increases in 
apparent clearance were also predicted in patients receiving 
doses lower than the recommended dose. The real clinical 
relevance of these ﬁ  ndings is still unknown. Pharmacokinetic 
features of adalimumab are summarized in Table 1.
The long-term immunogenicity of adalimumab is not 
known, although the drug is thought to be less immuno-
genic than the chimeric monoclonal antibody inﬂ  iximab. 
In three randomized RA trials, approximately 5% of 1062 
patients receiving adalimumab developed low-titer AAA 
at least once during treatment, which were neutralizing in 
vitro. The incidence of antibodies was greater at lower doses 
than at higher doses and among patients receiving EOW 
doses versus weekly doses (Anderson 2005). In RA patients, 
concomitant MTX therapy was associated with a reduced 
incidence of AAA formation as compared to adalimumab 
monotherapy (1% versus 12%). In patients with ankylosing 
spondylitis and PsA, the rate of development of AAA was 
comparable to patients with RA, although in PsA patients 
receiving concomitant MTX the rate was higher than that 
observed in RA patients (7% versus 1%). In patients with 
Crohn’s disease, the rate of AAA development was 2.6%. 
There was no apparent correlation of AAA development to 
adverse events, in terms of both frequency and pattern. In
RA patients receiving the recommended dosage of 40 mg 
EOW as monotherapy, no signiﬁ  cant difference in clinical 
response rate at week 26 was detected between AAA-positive 
patients and AAA-negative patients (van de Putte et al 
2004). However, the evaluation of the inﬂ  uence of AAA 
on the clinical response had produced contradictory results 
so far. A recent study investigated the prevalence of AAA 
development and their clinical relevance in a cohort of 121 
consecutive RA patients treated with 40 mg EOW (Bartelds 
et al 2007). AAA were detected in 21 patients (17%) during 
28 weeks of treatment. High concentrations of AAA were 
associated with non-response to adalimumab therapy, as well 
as with lower serum adalimumab concentrations. Interesting-
ly, restoration of clinical response after the increase of dosing 
frequency in patients who were previously non-responders 
was associated with the disappearance of AAA.
The data regarding the immunogenicity of adalimumab 
are dependent on the sensitivity and speciﬁ  city of the differ-
ent assays used to detect AAA which are not standardized. 
Moreover the reported rate of antibody positivity in an as-
say may be inﬂ  uenced by several factors including sample 
handling, timing of sample collection, underlying disease, 
concomitant medications, and especially the concentration 
of adalimumab in the serum. In fact, the presence of adalim-
umab may interfere with the assay so that patients with high 
serum concentrations of the drug are expected to have AAA 
undetectable. This means that the actual incidence of AAA 
can be underestimated and that high levels of AAA are more 
likely to be detected when adalimumab concentrations are 
absent or low (Bartelds et al 2007; Bender et al 2007).
Awaiting more information about the clinical signiﬁ  cance 
of AAA, useful hints can be suggested by taking into account 
the current knowledge on the immunogenicity of inﬂ  iximab 
(Vena and Cassano 2007). Development of anti-inﬂ  iximab 
antibodies has been reported in 14% to 61% of patients 
treated with inﬂ  iximab; antibody detection was found to be 
inversely related to the dosage of inﬂ  iximab and more fre-
quently associated with maintenance treatment with episodic 
infusions as compared to regular scheduled infusions every 
8 weeks. Anti-inﬂ  iximab antibodies can increase the clear-
ance of inﬂ  iximab (Rojas et al 2005), thus causing a more
rapid decline of serum concentrations of the drug. Positiv-
ity of anti-inﬂ  iximab antibodies does not preclude clinical 
responsiveness, although it can inﬂ  uence the rate of sustained 
response in the long term. In clinical practice, when response 
to inﬂ  iximab is reduced, it can be restored through dose Biologics: Targets & Therapy 2007:1(2) 96
Vena and Cassano
escalation (Rutgeerts et al 2006) which can counteract the 
loss of stable serum concentrations of inﬂ  iximab. The con-
comitant use of MTX or other immunosuppressants has been 
reported to reduce the incidence of anti-inﬂ  iximab antibodies, 
but it is not recommended in psoriasis. Recently, a study car-
ried out in RA patients disclosed that levels of anti-inﬂ  iximab 
antibodies were only slightly reduced by concomitant MTX 
and were not inﬂ  uenced by other antirheumatic drugs or 
prednisone (Bendtzen et al 2006).
Pharmacodynamics and mechanism
of action in psoriasis
The mechanism of action of adalimumab is primarily linked 
to the neutralization of TNF-alpha bioactivity by prevent-
ing the interaction of TNF-alpha with the cell surface TNF 
receptors. Through this mechanism, adalimumab inhibits 
several TNF-alpha-induced events, ie, the release of serum 
cytokines (IL-6), acute phase reactants of inﬂ  ammation, 
matrix metalloproteases and other markers of cartilage and 
synovium turnover, and the expression of adhesion molecules 
responsible for leukocyte migration (Mease 2005).
Like inﬂ  iximab, adalimumab lyses TNF-expressing cells 
in the presence of complement. The induction of apoptosis 
in activated mononuclear cells, via activation of intracellular 
caspase, is considered a relevant mechanism in Crohn’s dis-
ease treatment (Shen et al 2005, 2006). Instead, the exact role 
of apoptosis in the mechanism of action of TNF-blockers in 
either rheumatic diseases and psoriasis is still unknown.
In a study of 64 RA patients, treatment with adalimumab 
caused no signs suggestive of depression of delayed-type 
hypersensitivity and immunoglobulin levels, as well as no 
change in counts of T- and B-cells and NK-cells, monocyte/
macrophages, and neutrophils (Mease 2005).
A recent study gave interesting hints to elucidate the 
pathophysiological role of Langerhans cells in psoriasis 
and to understand the mechanism of action of adalimumab 
(Gordon et al 2005). A signiﬁ  cant reduction in the absolute 
number and density of epidermal Langerhans cells was dis-
covered in untreated psoriatic skin as compared to uninvolved 
skin from psoriatic patients. The depletion of Langerhans 
cells appeared to be speciﬁ  c for psoriatic plaques and was 
not detected in nonpsoriatic skin lesions characterized by 
hyperkeratosis, including nonimmune-mediated conditions, 
such as seborrhoeic keratoses, or lichen planus which is an 
inﬂ  ammatory skin disorder associated to the secretion of type 
I cytokines. Results obtained in the mouse xenograft model 
suggested that the decrease in epidermal Langerhans cells is 
an early event during plaque formation. Effective treatment 
with adalimumab in psoriatic patients restored the density 
of epidermal Langerhans cells in lesional skin, supporting 
that these cells may have an antiinﬂ  ammatory role and are 
crucially involved in the physiological differentiation of 
keratinocytes. The increase of Langerhans cells was already 
evident within 7 days of adalimumab treatment, when clinical 
response was not yet evident.
Clinical trials of adalimumab
in psoriasis
Preliminary data from PsA studies
All TNF-blockers, including adalimumab, were investigated 
in rheumatic diseases prior to psoriasis, so that the ﬁ  rst data 
Table 1 Synopsis of pharmacokinetic features of adalimumaba
Bioavailability  64% (single 40 mg dose)
Cmaxb (mg/L)  4.7 ± 1.6 (single 40 mg dose)
 7.7  ± 3.4 (steady state, 40 mg EOWc)
Tmaxd (hours)  131 ± 56 (single 40 mg dose)
AUC (mg h/L), steady state  1830 ± 850 (40 mg EOW)
Vsse (L)  4.7–6.0 
Mean steady-state levels (mg/L)  5 (40 mg EOW without MTXf  )8–9 (40 mg EOW with MTX). Higher with higher doses and slightly higher in 
 PsAg (6–10 mg/L without MTX and 8.5–12 mg/L with MTX)
Half-life (days), single dose  10–20 (mean, 2 weeks)
Systemic clearance (L/h)  0.012
  Apparently reduced with concomitant MTX by 29% (after single dosing) and 44% (after multiple    
  dosing). Possibly lower with increasing age (ie, in patients aged 40 to 75 years) 
 Possibly  higher:
    –  with increasing body weight 
    –  in patients receiving doses lower than the recommended dose 
   – in  the  presence  of  AAAh 
aData reported in Humira® Prescribing Information (FDA - label approved on 26/02/2007; EMEA – Rev. 7, published on 02/07/07);   bCmax, maximum serum concentration; 
cEOW, every other week; dTmax, time to reach the maximum concentration;   eVss, distribution volume;   fMTX, methotrexate;   gPsA, psoriatic arthritis;   hAAA, anti-adalimumab 
antibodies.Biologics: Targets & Therapy 2007:1(2) 97
Adalimumab in psoriasis
documenting the potential effectiveness in psoriasis were 
suggested by the subanalysis of the effect on concomitant 
skin lesions in patients enrolled in PsA trials.
The Adalimumab Effectiveness in PsA Trial (ADEPT) 
study was a phase III, 24-week, randomized, parallel-group, 
placebo-controlled, double-blind study which evaluated the 
efﬁ  cacy and safety of adalimumab in patients with moder-
ately to severely active PsA who had a history of inadequate 
response or intolerance to non-steroidal anti-inﬂ  ammatory 
drugs (Mease et al 2005). MTX use was permitted during the 
study only if it had been taken for at least 3 months previously 
and was maintained at a stable dosage for a minimum of 4 
weeks before treatment start. A total of 315 patients were 
randomized to receive s.c. injections of placebo (n = 162) 
or 40 mg adalimumab (n = 151) given EOW for 24 weeks. 
Nearly half of the patients in both groups were receiving 
MTX at baseline. In brief, the cumulative results showed that, 
as compared to placebo, adalimumab signiﬁ  cantly improved 
the signs and symptoms of PsA and the physical-related func-
tional disability, and inhibited the radiographic progression 
of arthritis. The response of PsA to adalimumab was rapid 
and sustained throughout the 24-week treatment period and 
did not differ between patients treated with adalimumab as 
monotherapy and those receiving concomitant MTX.
The inﬂ  uence of adalimumab treatment on concomitant 
skin lesions was considered a secondary efﬁ  cacy endpoint 
in patients whose psoriasis involved at least 3% of the BSA. 
A total of 138 patients (69 patients in each group) underwent 
skin assessment. Evaluation of these patients was performed 
using the PASI, and the physician’s global assessment (PGA), 
as well as the Dermatology Life Quality Index (DLQI) 
(Finlay and Khan 1994). PASI response was rated as the 
proportion of patients who exhibited at least a 50%, 75% or 
90% improvement of PASI from baseline (PASI 50, PASI 
75, and PASI 90, respectively). Signiﬁ  cant differences in 
the PASI response rates between the active treatment and 
placebo groups were evident as early as week 4. At week 12, 
the PASI 50, PASI 75 and PASI 90 responses were obtained 
in 72%, 49% and 30% of patients (compared with 15%, 4%, 
and 0% in the placebo-treated patients), respectively. The 
results achieved with adalimumab were sustained at week 
24, when patients who met the PASI 50, PASI 75 and PASI 
90 response criteria were 75%, 59%, and 42% (versus 12%, 
1% and 0% in patients receiving placebo), respectively. 
PASI improvements were independent on the severity of 
baseline psoriasis and did not differ between patients who 
had mild to moderate psoriasis (PASI 10) or moderate to 
severe disease (PASI  10) at baseline. Results of the PGA 
showed that 67% of patients receiving adalimumab therapy 
achieved either ‘clear’ or ‘almost clear’ ratings by week 24 
(as compared to 10% in the placebo group). Clinical results 
were paralleled by DLQI improvement, with a mean change 
from baseline of −6.1 versus −0.7 in the adalimumab-treated 
patients compared with the placebo group. A complete reso-
lution of skin-related functional improvement (DLQI = 0) 
was achieved in 43.6% of patients receiving adalimumab 
therapy versus 5% of those treated with placebo by week 24 
(Gladman et al 2007a).
Patients who completed the 24-week double-blind phase 
of ADEPT were eligible to enter an open-label extension 
trial with s.c. adalimumab, 40 mg EOW, until the drug was 
commercially available and for a maximum of 120 weeks. 
Patients who failed to achieve at least a 20% improvement in 
both swollen and tender joint counts after at least 12 weeks of 
the open-labeled treatment could be treated with adalimumab 
40 mg given every week. Clinical results at week 48 have 
been recently published and showed the sustained effect 
of adalimumab at a dosage of 40 mg EOW on clinical and 
radiographic outcomes of PsA, as well as on PASI responses, 
regardless of the use of concomitant MTX (Gladman et al 
2007b). Patients who required dose escalation on or after 
week 36 were 15 in the group treated with adalimumab in 
the blinded phase (total n = 138) and 23 of the 147 patients 
from the original placebo arm. Moreover, continuous treat-
ment with adalimumab 40 mg EOW led to a sustained 
improvement of skin lesions through week 48, when the 
mean PASI improvement from baseline was 68% and the 
PASI 50, PASI 75 and PASI 90 responses were observed 
in 67%, 58% and 46% of patients, respectively. Notably, 
at week 48, 33% of these patients were completely cleared 
(= PASI 100 responders). Patients treated with placebo 
during ADEPT achieved a 64% mean improvement in the 
PASI score after 24 weeks of the open-label adalimumab 
therapy, which allowed the achievement of the PASI 50, 
PASI 75, PASI 90 and PASI 100 response rates of 61%, 
53%, 44%, and 31%, respectively. Patients with psoriasis 
who underwent dose escalation on or after week 36 were 
8 of the 69 patients from the adalimumab trial and 12 of 
the 59 patients from the placebo arm. Subsequent post-hoc 
subanalyses of ADEPT showed that the clinical efﬁ  cacy of 
adalimumab against PsA and psoriasis at weeks 24 and 48 
did not vary according to PsA duration at baseline (Choy 
et al 2007) and that the PASI 100 response was associated 
with a better dermatology-related quality of life than PASI 
75–99 response as deﬁ  ned by the proportion of patients with 
DLQI of 0 or 1 (95% versus 68%) (Gladman et al 2007c).Biologics: Targets & Therapy 2007:1(2) 98
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Psoriasis studies
The results of a phase II, 12-week, randomized, double-blind, 
placebo-controlled study (M02-528) with adalimumab in 
147 patients with moderate to severe psoriasis have been 
recently published (Gordon et al 2006). The publication 
also included the results of a subsequent 48-week extension 
phase (M02-529). Eligible patients included adult patients 
with moderate to severe plaque psoriasis of at least 1-year 
duration and involving 5% or more of their BSA. Patients 
who had been treated with anti-TNF treatment were excluded. 
Concomitant psoriasis therapies were not allowed with the 
exception of low- to mid-potency corticosteroids applied 
topically to the palms, soles, face, and groin. In the initial 
study, patients were randomized 1:1:1 to receive s.c. injec-
tions of: a) 80 mg of adalimumab at week 0 followed by 40 
mg EOW from week 1 onward; b) 80 mg of adalimumab at 
weeks 0 and 1 followed by 40 mg per week; or c) placebo 
weekly from week 0. Patients who completed this initial 
trial were eligible to continue in the extension trial, in which 
patients who received adalimumab during the initial study 
continued their assigned dosages, whereas placebo group 
was switched to 80 mg of the active drug at week 12, and 
40 mg EOW beginning at week 13. In weeks 13–24, patients 
remained blinded to the frequency of adalimumab therapy. In 
the subsequent open-label phase (weeks 25–60), patients in 
the placebo/EOW and EOW groups were eligible for dosage 
escalation (to adalimumab 40 mg per week) if they had less 
than PASI 50. Patients who required dose escalation were 
regarded as non-responders in the primary analysis.
A statistically signiﬁ  cant improvement in mean PASI 
score occurred as early as week 1 and a higher percentage 
of PASI 50 responders in both the adalimumab treatment 
arms was observed by week 2 as compared to placebo. Clini-
cal response rates did not appear to be inﬂ  uenced by sex, 
age, or body weight of patients and by baseline severity of 
psoriasis. After 12 weeks of treatment, 53% of patients who 
received 40 mg of adalimumab EOW and 80% of patients 
who received 40 mg/week of adalimumab achieved the 
PASI 75, compared with 4% of patients treated with placebo. 
The response to adalimumab was sustained through week 60 
in the majority of patients. Details of PASI response rates 
over the study period are shown in Table 2.
Between weeks 24 and 60, 34 patients (18 from the 
placebo/EOW group, 12 from the EOW group, and 4 from 
the weekly group) did not achieve the PASI 50 response and 
were therefore eligible for dose escalation. Among the 30 
patients from the placebo/EOW and EOW groups, PASI 50 
and 75 rates at week 60 were 40% and 17%, respectively. This 
suggests that dose escalation may restore response in some 
patients. It would have been interesting to have data about the 
development of AAA and adalimumab serum concentrations 
and to correlate these aspects to clinical response, but these 
ﬁ  ndings were unfortunately not available for this study.
The sample size analyzed and the open-label design of a 
portion of the extension phase did not allow reliable assessment 
of data about the efﬁ  cacy of EOW versus weekly treatment. 
However, the results seem to indicate that the weekly dosing 
was more rapid for the achievement of meaningful responses 
(PASI 75 up to PASI 100) at week 12 and was associated with 
greater PASI 90–100 rates at week 60 than EOW dosing.
A subgroup analysis of this phase II trial revealed that 
long-term adalimumab treatment caused a meaningful 
improvement of quality of life whose magnitude appeared 
to be dependent on the response rate (Gordon et al 2007). In 
fact, at week 60, patients with PASI 50, 50–74, 75–99, and 
100 had mean reductions from baseline in DLQI of 6.0, 8.8,
11.5, and 11.1, respectively. At week 60, a DLQI score of 0 
was achieved by 0%, 28%, 37%, and 79% of patients with 
PASI 50, 50–74, 75–99, and 100 responses, respectively. 
After the completion of the extension M02-529 trial, patients 
entered in a phase III open-label extension study (M03-658) 
which evaluated the long-term efﬁ  cacy and safety of con-
tinuous administration of adalimumab 40 mg EOW (Papp 
et al 2007). Among patients who continued to be treated 
(n = 49), PASI responses were generally maintained up to 
week 120.
Results from randomized controlled phase III trails of 
adalimumab in moderate to severe psoriasis have recently 
presented and are summarized in Table 3. The M03-656 
(REVEAL) study conﬁ  rmed the effectiveness of treatment 
with adalimumab 80 mg at week 0 and 40 mg EOW from 
week 1 to week 15 versus placebo (Menter et al 2007). 
Efﬁ  cacy was sustained during open-label treatment with 
adalimumab. At week 33, PASI 75 responders were 
re-randomized to continue adalimumab 40 mg EOW or 
receive placebo treatment up to week 52. During this period, 
28.4% of subjects receiving placebo experienced a loss of 
adequate response (deﬁ  ned as either a response less than 
PASI 50 relative to baseline or a  6-point increase in PASI 
from weeks 34 to 52 relative to week 33) compared to 4.9% 
of patients still receiving adalimumab. The CHAMPION 
study compared for the ﬁ  rst time a biologic agent (adalim-
umab) with a traditional systemic drug (MTX) in patients 
with moderate to severe chronic plaque psoriasis (Saurat 
et al 2006). Adalimumab demonstrated signiﬁ  cantly superior 
efﬁ  cacy versus MTX and versus placebo.Biologics: Targets & Therapy 2007:1(2) 99
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Table 2 Phase II trial of adalimumab in moderate to severe psoriasis (M02-528 and M02-529 studies): response rates
Visit Responsea  Placebo/Adalimumab  Adalimumab 40 mg  Adalimumab 40 mg per
   40  mg  EOWb (% of patients)  EOW (% of patients)  week (% of patients)
Week 12  PASI 50  NAc 76  88
 PASI  75  4  53  80
 PASI  90  NA  24  48
 PASI  100  0  11  26
Week 24  PASI 75  55  64  72
 PASI  100  11  13  24
Week 36  PASI 75  57  62  68
 PASI  100  19  22  36
Week 60  PASI 50  57  64  66
 PASI  75  45  56  64
 PASI  90  40  33  48
 PASI  100  19  16  26
Patients in the placebo group were switched to adalimumab 40 mg EOW at week 12.
aResponse deﬁ  ned as the improvement of the Psoriasis Area and Severity Index (PASI) of at least 50% (PASI 50), 75% (PASI 75), 90% (PASI 90) and 100% (PASI 100) from 
baseline; bEOW, every other week; cNA, not available.
Table 3 Randomized controlled phase III trials of adalimumab in moderate to severe psoriasis: Synopsis of study characteristics and 
efﬁ  cacy results
Study/Reference  Patients and study design   Efﬁ  cacy results
M03-656 (REVEALa)  A multicenter, 52-week, randomized study in 1,212 patients with a  Period  A – PASI 75 response for adalimumab
/Menter et al 2007  diagnosis of plaque psoriasis for at least 6 months, and with a    – at week 8: 54.1% (vs 3% for placebo);
 PASIb 12, and affected BSAc 10%, all naïve to anti-TNFd therapy    – at week 12: 67.7% (vs 4.8% for placebo);
          – at week 16: 71% (vs 6.5% for placebo)
 Three  sequential  phases: 
  •  Period A (16 weeks) – double-blind, placebo-controlled phase; 2:1  Period B – Mean PASI improvement achieved at
    randomization to:  week 16 was maintained through week 33
    –  adalimumab 80 mg at week 0 and 40 mg EOWe thereafter (n = 814)  Period C – Loss of adequate responseg for
   –  placebo  (n  = 398)  adalimumab (vs placebo): 4.9% (vs 28.4%)
  •  period B (17 weeks) - open-label phase in patients with PASI 75f 
    response at week 16: n = 580 in the adalimumab group (who continued 
    to receive 40 mg EOW), and n = 26 in the placebo group (who began 
    adalimumab 80 mg at week 16 followed by 40 mg EOW) 
  •  period C (19 weeks) - double-blind, placebo-controlled phase in 
    PASI 75 responders at week 33; 1:1 randomization to:
    –  adalimumab 40 mg EOW (n = 250)  
   –  placebo  (n  = 240) 
CHAMPIONh/  A multicenter, 16-week, randomized, double-blind double-dummy,  PASI 75 response for adalimumab
Saurat et al 2006  placebo-controlled study in 271 patients with a diagnosis of psoriasis    – at week 8: 62% (vs 13% for placebo 
  for at least 1 year, and with a PASI  10 and affected BSA  10%,      and 9% for MTX);
  all naive to both anti-TNF treatment and MTXi    – at week 12: 77%  (vs 15% for placebo
  2:2:1 Randomization to:      and 25% for MTX);
    –  adalimumab 80 mg at week 0, followed by 40 mg EOW (n = 108);    – at week 16: 80% (vs 19% for placebo
    –  oral MTX 7.5 mg at weeks 0 and 1, 10 mg at weeks 2 and 3, and      and 36% for MTX)
      15 mg from week 4 onward (n = 110); the weekly dose was reduced  
      in case of safety problems from week 2 until week 15, or increased 
      to 20 mg at week 8, and 25 mg at week 12 if PASI 50 was not 
      achieved in the absence of safety concerns 
   –  placebo  (n  = 53) 
aREVEAL, Randomized Controlled Evaluation of adalimumab Every other week dosing in moderate to severe psoriasis triAL; bPASI, Psoriasis Area and Severity Index; cBSA, 
body surface area; dTNF, tumor necrosis factor; eEOW, every other week; fPASI 75, PASI improvement of at least 75% from baseline; gLoss of adequate response deﬁ  ned 
as either response  PASI 50 relative to baseline or a 6-point increase in PASI at weeks 34–52 relative to week 33; hCHAMPION, Comparative Study of HUMIRA vs 
Methotrexate vs Placebo In PsOriasis PatieNts; iMTX, methotrexate.Biologics: Targets & Therapy 2007:1(2) 100
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Other considerations about treatment 
with adalimumab in psoriasis
Rheumatologic experience has suggested that switching to 
adalimumab can restore a good clinical response in patients 
with loss of efﬁ  cacy from other anti-TNF biologics, inﬂ  ix-
imab or etanercept, over time (Wick et al 2005). Adalimumab 
treatment was also found to be beneﬁ  cial for patients with 
Crohn’s disease who experienced loss of response or intoler-
ance to inﬂ  iximab (Sandborn et al 2004).
Preliminary data from small series of psoriatic patients 
show that adalimumab can be effective for patients whose 
psoriasis was refractory to inﬂ  iximab and etanercept and 
can reestablish the PASI 75 response in patients who did 
not maintain this level of response after step-down dosing 
of etanercept from 50 mg twice weekly to 50 mg weekly 
(Pitarch et al 2007; Yamauchi 2007).
An ever-growing number of case reports have docu-
mented the possible occurrence of psoriasis exacerbation 
during treatment with TNF-inhibitors, as well as that of 
new-onset psoriasis or psoriasis-like lesions in patients 
without history of psoriasis and undergoing anti-TNF therapy 
for other conditions, especially RA (Cohen et al 2007; de 
Gannes 2007; Fiorentino 2007; Goiriz et al 2007). These 
paradoxical phenomena have been reported with all the 
available anti-TNF-alpha biologics, including adalimumab. 
Flare of skin lesions in psoriasis patients often involved 
areas previously unaffected and developed as new clinical 
variants (eg, ﬂ  exural psoriasis, eruptive guttate psoriasis, or 
palmoplantar pustulosis) never presented by patients in their 
lifetime. The outcome of reactions was variable, consisting of 
either worsening requiring discontinuation of the anti-TNF, 
or complete resolution despite continuation of the anti-TNF, 
often after use of topical anti-psoriasis drugs or other rescue 
treatments. The mechanisms of these reactions are not known, 
although several hypotheses may be suggested, such as the 
involvement of autoimmune phenomena or effector cytokines 
other than TNF-alpha (including interferon-alpha), the dual 
opposite effects of TNF-alpha on immune homeostasis and 
apoptosis, and the triggering effect of infectious factors.
Safety proﬁ  le of adalimumab
The absence of cumulative organ-speciﬁ  c toxicity of biologic 
therapies creates the premises for the innovative concept 
of a long-term continuous treatment to control psoriasis. 
However, there are other potential safety issues related to 
biologic therapy. Although the available evidences support 
the favorable safety proﬁ  le of biologic agents for psoriasis, 
long-term follow-up in large sample populations is required 
to obtain more precise information, particularly about uncom-
mon adverse events. In the meantime, a positive risk/beneﬁ  t 
ratio may be preserved through careful selection of patients 
and monitoring, based on the recommendations of the manu-
facturing companies and consensus guidelines (Smith et al 
2005). Table 4 shows the recommendations reported in the 
prescribing guidelines of adalimumab.
Due to the importance of TNF in host defense, one of the 
issue of major concern with all TNF-blockers, including adali-
mumab, is the increased risk of infections and malignancies 
(Scheinfeld 2005; Desay and Furst 2006). The most important 
infectious complication is the reactivation of tuberculosis (TB), 
whose incidence has decreased following implementation of 
TB screening (Schiff et al 2006). In post-marketing experience 
with adalimumab, TB, frequently disseminated or extrapul-
monary, and other opportunistic infections have been reported 
(Orenstein 2006). The overall rate of TB in clinical studies 
involving over 13,000 patients was 0.26 per 100 patient-years, 
and 0.07 per 100 patient-years over 4500 patients in the US 
and Canada. The risk of TB increased with doses of adalim-
umab higher than those recommended. In placebo-controlled 
studies, the most common infections were bronchitis, upper 
respiratory tract and urinary tract infections.
A double-blind, randomized study demonstrated that adult 
RA patients treated with adalimumab can be effectively and 
safely immunized with pneumococcal and inﬂ  uenza vaccines 
(Kaine et al 2007). Percentages of patients achieving a vaccine 
response were similar in the adalimumab and placebo groups fol-
lowing pneumococcal vaccination and lower with adalimumab 
than placebo following inﬂ  uenza vaccination. Instead, propor-
tions of patients with protective antibody titers were similar in 
both treatment groups following each type of vaccination.
The potential role of TNF inhibitors in the development 
of malignancies is not known. Adverse event reporting 
and cohort studies have failed to demonstrate any linkage 
between the development of solid tumors and anti-TNF 
therapy. Patients with chronic inﬂ  ammatory diseases, such 
as RA, are known to be at higher risk for the development 
of lymphoma, in apparent correlation to longstanding high 
disease activity. Some evidences indicated that RA patients 
treated with TNF-blocking agents, including adalimumab, 
do not have higher lymphoma risks than other patients with 
RA (Desay and Furst 2006; Schiff et al 2006).
In clinical trials of adalimumab, 12% of treated patients 
versus 7% of the placebo group developed anti-nuclear antibod-
ies. However, development of a lupus-like syndrome appears to 
be uncommon during treatment with adalimumab or other anti-
TNF drugs. Due to the frequent occurrence of autoantibodies Biologics: Targets & Therapy 2007:1(2) 101
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during anti-TNF therapy, they are considered without clinical 
relevance, unless symptoms suggestive of lupus-like syndrome 
develop. Therefore, measurement of anti-nuclear antibodies and 
anti-dsDNA is not required during treatment with TNF-alpha 
antagonists (Vena and Cassano 2007).
Other safety problems rarely associated with TNF-blockers, 
including adalimumab, are represented by blood dyscrasias, 
including thrombocytopenia, leukopenia and pancytopenia, new 
onset or exacerbation of congestive heart failure and worsening or 
initiation of multiple sclerosis and other demyelinating disorders 
(Scheinfeld 2005; Desay and Furst 2006).
Safety data from the psoriasis studies were comparable to 
those of previous studies of adalimumab in RA and PsA. The 
overall incidence of adverse events did not differ between adali-
mumab and placebo, and, in the CHAMPION study, among 
adalimumab, placebo and MTX groups, and it remained stable 
over long-term treatment periods up to 120 weeks (Gordon et al 
2006; Saurat 2006; Menter et al 2007; Papp et al 2007).
In all studies of adalimumab, the most frequent side effect 
was injection site reaction, which was generally mild to mod-
erate and transient, and did not require drug discontinuation. 
In placebo-controlled trials, injection site reactions were 
reported in 17%–20% of patients treated with adalimumab 
(versus 11%–14% of patients receiving placebo).
In the ADEPT, elevations in transaminases were more 
common in adalimumab-treated patients than placebo-treated 
patients. The majority of these elevations were transient, and 
occurred primarily in patients who were receiving concomi-
tant hepatotoxic drugs, such as MTX (Mease 2005).
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